Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 20/100

Failure Rate

12.7%

8 terminated/withdrawn out of 63 trials

Success Rate

82.2%

-4.3% vs industry average

Late-Stage Pipeline

48%

30 trials in Phase 3/4

Results Transparency

92%

34 of 37 completed trials have results

Key Signals

11 recruiting34 with results6 terminated

Enrollment Performance

Analytics

Phase 3
23(42.6%)
Phase 2
12(22.2%)
Phase 1
12(22.2%)
Phase 4
7(13.0%)
54Total
Phase 3(23)
Phase 2(12)
Phase 1(12)
Phase 4(7)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (63)

Showing 20 of 63 trials
NCT05714969Phase 2Completed

A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

Role: collaborator

NCT01887938Phase 1Completed

An Efficacy and Safety Study of HGT-1110 in Participants With Metachromatic Leukodystrophy

Role: collaborator

NCT03771898Phase 2Active Not Recruiting

A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy

Role: collaborator

NCT04085172Phase 4Completed

A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)

Role: collaborator

NCT07042685Phase 2Recruiting

Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer

Role: collaborator

NCT06076642Phase 3Active Not Recruiting

A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases

Role: collaborator

NCT02455622Phase 4Completed

Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age

Role: collaborator

NCT04683003Phase 3Active Not Recruiting

A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

Role: collaborator

NCT07298343Phase 2Recruiting

Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac Disease

Role: collaborator

NCT07011576Phase 2Recruiting

A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)

Role: collaborator

NCT06980480Phase 3Recruiting

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

Role: collaborator

NCT03196427Phase 2Completed

Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Role: collaborator

NCT06252493Recruiting

Value of PET/MR Enterography in the Assessment of Crohn's Disease Using a Collagen-binding Radiotracer.

Role: collaborator

NCT05677971Phase 3Recruiting

Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Role: collaborator

NCT03393975Phase 3Completed

A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)

Role: collaborator

NCT07270991Phase 3Recruiting

Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric Adenocarcinoma

Role: collaborator

NCT05755035Phase 2Completed

A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

Role: collaborator

NCT05156983Phase 3Recruiting

A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery

Role: collaborator

NCT04259138Phase 4Active Not Recruiting

Determination of the Optimal Treatment Target in Ulcerative Colitis

Role: collaborator

NCT05556629Completed

A Survey to Assess Participants' and Physicians' Knowledge, Attitudes and Behavior When Using NATPARA

Role: collaborator